Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

2017 ESMO Congress
Tweet this page

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Advertisement

Advertisement



Advertisement